What is the most recent earnings date for YMAB stock?
Y-MABS THERAPEUTICS INC (YMAB) last reported earnings on 8/8/2025.
Y-MABS THERAPEUTICS INC (YMAB) Earnings History & Surprises
NASDAQ:YMAB • US9842411095
Current stock price
8.61 USD
+0.02 (+0.23%)
At close:
8.61 USD
0 (0%)
After Hours:
YMAB Earnings overview
Past quarterly earnings results for Y-MABS THERAPEUTICS INC (YMAB), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Nov 6, 2025
- Period
- Q3 / 2025
- EPS Estimate
- -$0.22
- Revenue Estimate
- 21.437M
Last Reported
Most Recent- Release Date
- Aug 8, 2025
- Period
- Q2 / 2025
- EPS Reported
- -$0.07
- EPS Surprise
- 74.16%
- Revenue Surprise
- 4.07%
Beat Rate
Last 8 Quarters 50%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2025 | -0.07 | -0.27 | 74.16% | 66.67% | 19.525M | 18.762M | 4.07% | -14.36% |
| Q1 2025 | -0.12 | -0.22 | 44.37% | 20.00% | 20.904M | 19.997M | 4.54% | 4.88% |
| Q4 2024 | -0.15 | -0.13 | -18.84% | -650.00% | 26.495M | 27.835M | -4.81% | 13.41% |
| Q3 2024 | -0.16 | -0.16 | 0.40% | 11.11% | 18.461M | 23.728M | -22.20% | -9.74% |
| Q2 2024 | -0.21 | -0.13 | -56.65% | -50.00% | 22.798M | 23.479M | -2.90% | 9.86% |
| Q1 2024 | -0.15 | -0.14 | -8.29% | - | 19.931M | 22.664M | -12.06% | -1.58% |
| Q4 2023 | -0.02 | -0.21 | 90.24% | -166.67% | 23.363M | 21.374M | 9.31% | -25.71% |
| Q3 2023 | -0.18 | -0.19 | 5.56% | 71.43% | 20.454M | 21.348M | -4.19% | 63.11% |
| Q2 2023 | -0.14 | -0.25 | 43.21% | 85.11% | 20.751M | 20.176M | 2.85% | 92.14% |
| Q1 2023 | -0.15 | -0.32 | 53.84% | 76.56% | 20.251M | 15.864M | 27.65% | 93.05% |
| Q4 2022 | 0.03 | -0.47 | 106.45% | 103.53% | 31.45M | 20.464M | 53.68% | 227.60% |
| Q3 2022 | -0.63 | -0.72 | 13.01% | 4.55% | 12.54M | 12.248M | 2.38% | 39.80% |
| Q2 2022 | -0.94 | -0.68 | -38.47% | -77.36% | 10.8M | 11.441M | -5.60% | -1.37% |
| Q1 2022 | -0.64 | -0.73 | 12.45% | 5.88% | 10.49M | 11.119M | -5.66% | 94.98% |
| Q4 2021 | -0.85 | -0.72 | -18.32% | -77.08% | 9.6M | 11.037M | -13.02% | -53.73% |
| Q3 2021 | -0.66 | -0.61 | -8.20% | 19.51% | 8.97M | 11.092M | -19.13% | - |
| Q2 2021 | -0.53 | -0.68 | 21.98% | 47.52% | 10.95M | 7.474M | 46.51% | - |
| Q1 2021 | -0.68 | 0.19 | -450.88% | -3.03% | 5.38M | 45.359M | -88.14% | - |
| Q4 2020 | -0.48 | -0.52 | 7.12% | - | 20.75M | 15.854M | 30.88% | - |
| Q3 2020 | -0.82 | -0.80 | -2.41% | - | - | - | ||
| Q2 2020 | -1.01 | -0.69 | -46.57% | - | - | - | ||
| Q1 2020 | -0.66 | -0.64 | -3.81% | - | 45.329K | -100.00% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
25.03%
Max EPS beat (4)
74.16%
Min EPS beat (4)
-18.84%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
-4.60%
Max Revenue beat (4)
4.54%
Min Revenue beat (4)
-22.20%
Analysis
In the last 4 quarters, YMAB has beaten EPS estimates in 3 out of 4 releases
YMAB has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, YMAB has beaten the EPS estimates by 25.0% on average.
In the last 4 quarters, YMAB reported -4.6% below the revenue estimates on average.
Related analysis
Y-MABS THERAPEUTICS INC / YMAB Earnings FAQ
Did Y-MABS THERAPEUTICS INC (YMAB) beat earnings estimates last quarter?
Y-MABS THERAPEUTICS INC (YMAB) beat EPS estimates and beat revenue estimates in the most recent quarter.
Can you provide information on how often Y-MABS THERAPEUTICS INC beats earnings estimates?
In the last 4 quarters, Y-MABS THERAPEUTICS INC (YMAB) has beaten EPS estimates in 3 out of 4 releases.